Drug Trial Radar · NCT03962543
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
114
Actual
Start
Sep 29, 2019
Primary completion
Sep 20, 2023
Study completion Dec 22, 2028
Sponsor
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- May 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.
Conditions
- Plexiform Neurofibroma
- Neurofibromatosis Type 1 (NF1)
Interventions
Mirdametinib (PD-0325901) oral capsule or dispersible tabletDrug
Mirdametinib (PD-0325901) capsule or dispersible tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate at the End of the Treatment Phase.Time frame: Up to 24 months
Locations
43 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB) - Children's of Alabama
Birmingham, Alabama
Mayo Clinic Arizona
Phoenix, Arizona
Arkansas Children's Hospital - University of Arkansas
Little Rock, Arkansas
Children's Hospital Los Angeles
Los Angeles, California
University of California, Los Angeles (UCLA)
Los Angeles, California
Children's Hospital of Orange County
Orange, California
University of California - Irvine Health
Orange, California
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
University of California - Davis
Sacramento, California
Children's Hospital Colorado
Aurora, Colorado
Nemours A. I. duPont Hospital for Children
Wilmington, Delaware
Children's National Hospital
Washington D.C., District of Columbia
University of Florida (UF) - Gainesville
Gainesville, Florida
Nicklaus Children's Hospital
Miami, Florida
Florida Hospital Cancer Institute
Orlando, Florida
Arnold Palmer Hospital for Children
Orlando, Florida
Johns Hopkins All Children's Hospital
St. Petersburg, Florida
Moffitt
Tampa, Florida
University of Illinois Hospital
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa Health Care
Iowa City, Iowa
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
Saint Joseph's Regional Medical Center
Paterson, New Jersey
Albany Medical Center
Albany, New York
Children's Hospital at Montefiore
The Bronx, New York
University of North Carolina (UNC) Hospitals
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
UC Health
Cincinnati, Ohio
Nationwide Children's Hospital
Columbus, Ohio
University of Oklahoma - Health Sciences Center
Oklahoma City, Oklahoma
Oregon Health and Science University
Portland, Oregon
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt Children's Hospital
Nashville, Tennessee
University of Texas Southwestern
Dallas, Texas
Cook Children's Medical Center
Fort Worth, Texas
MD Anderson Cancer Center
Houston, Texas
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.